Leukemia drug shows promise against rare joint tumors

NCT ID NCT01207492

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested nilotinib, a drug originally used for leukemia, in 17 patients with relapsed or metastatic pigmented villonodular synovitis (PVNS) or related giant cell tumors. The goal was to see if the drug could stop tumor growth or improve symptoms. Results focused on how long patients lived without their disease getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Tumor of Tendon Sheath tenosynovial giant cell tumor tenosynovial giant cell tumor, diffuse type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Sarcoma Oncology Center

    Santa Monica, California, 90403, United States

  • Stanford University Medical Center

    Stanford, California, 94305, United States

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030, United States